-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The REFALS study is a randomized, double-blind, placebo-controlled phase 3 trial randomized, double-blind, placebo-controlled phase 3 trial
- Between June 21, 2018 and June 28, 2019, 871 people were screened for the study , and 496 of them were randomly assigned to levosimendan (n=329) or placebo (n=167)
In the majority of patients with amyotrophic lateral sclerosis, levosimendan is not superior to placebo in maintaining respiratory function
Cudkowicz M, Genge A, Maragakis N, et al.
Leave a message here